Grant: Idea to Innovation
University of British Columbia
$15,000.00
Products for detection and decontamination of cytotoxic agents
EF 2013-14
Résumé
Cytotoxic drugs are prepared and administered on a daily basis in Canadian hospitals, primarily for the treatment of various cancer types. According to the latest figures reported by the British Columbia Cancer Agency, there were 31,515 chemotherapy visits in 2007/2008. Although the therapeutic benefits of these drugs are indisputable, these drugs indiscriminately kill cells; many are inherently mutagenic and/or carcinogenic due to their mechanism of action as DNA alkylating agents. As such, chronic workplace exposure to these drugs is a major problem in the health industry. A significant factor is that common cleaning agents whose purpose is to decontaminate surfaces are ineffective at best and may actually exacerbate the problem, either by spreading the drugs to other surfaces or by decomposing the drugs into more toxic agents. Nanozen (a local company with whom we collaborate) has developed a simple, cost effective proprietary solution that removes >99.99% of tested drug residues from contaminated surfaces. The solutions effectively solubilizes contaminants, allowing them to be absorbed onto a ""wipe"" media that can be safely disposed. An additional critical need in hospitals is the ability to detect airborne and surface cytotoxic drugs to ensure their proper and complete removal from the workplace. Unfortunately, to date, no standard protocol has been developed measure the amount of exposure for health care workers. Through the NSERC Engage program, we have developed sensors for the detection of alkylating agents in collaboration with Nanozen. The goal of this market assessment is to determine which of the previous described options would be most desirable to hospital administrators and government regulators: (1) cleaning solution alone, (2) pre-formed wipes containing the cleaning solution (similar in principle to baby wipes), (3) wipes containing both the cleaning solution and sensor, (4) other formulations of the sensor (e.g., badge, device for detection of airborne particulates), (5) development of spill kits.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
461370-2014
Name nom
Love, Jennifer
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2014
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
1
Nb partie
1
Application title
Products for detection and decontamination of cytotoxic agents
Keyword
NSERC
Application summary
Cytotoxic drugs are prepared and administered on a daily basis in Canadian hospitals, primarily for the treatment of various cancer types. According to the latest figures reported by the British Columbia Cancer Agency, there were 31,515 chemotherapy visits in 2007/2008. Although the therapeutic benefits of these drugs are indisputable, these drugs indiscriminately kill cells; many are inherently mutagenic and/or carcinogenic due to their mechanism of action as DNA alkylating agents. As such, chronic workplace exposure to these drugs is a major problem in the health industry. A significant factor is that common cleaning agents whose purpose is to decontaminate surfaces are ineffective at best and may actually exacerbate the problem, either by spreading the drugs to other surfaces or by decomposing the drugs into more toxic agents. Nanozen (a local company with whom we collaborate) has developed a simple, cost effective proprietary solution that removes >99.99% of tested drug residues from contaminated surfaces. The solutions effectively solubilizes contaminants, allowing them to be absorbed onto a ""wipe"" media that can be safely disposed. An additional critical need in hospitals is the ability to detect airborne and surface cytotoxic drugs to ensure their proper and complete removal from the workplace. Unfortunately, to date, no standard protocol has been developed measure the amount of exposure for health care workers. Through the NSERC Engage program, we have developed sensors for the detection of alkylating agents in collaboration with Nanozen. The goal of this market assessment is to determine which of the previous described options would be most desirable to hospital administrators and government regulators: (1) cleaning solution alone, (2) pre-formed wipes containing the cleaning solution (similar in principle to baby wipes), (3) wipes containing both the cleaning solution and sensor, (4) other formulations of the sensor (e.g., badge, device for detection of airborne particulates), (5) development of spill kits.